SBSergio Mompart Barrenechea

Sergio Mompart Barrenechea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergio Mompart Barrenechea has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing PROTAC technology to combat stress hormone receptor activation

    by Mahshid Gazorpak, Karina M. Hugentobler, Dominique Paul, Pierre-Luc Germain, Miriam Kretschmer, Iryna Ivanova, Selina Frei, Kei Mathis, Remo Rudolf, Sergio Mompart Barrenechea, et al.

    Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology. This selective degrader enables immediate and reversible GR depletion that is independent of genetic manipulation and circumvents transcriptional adaptations to inhibition. KH-103 achieves passive inhibition, preventing agonistic induction of gene expression, and significantly averts the GR’s genomic effects compared to two currently available inhibitors. Application in primary-neuron cultures revealed the dependency of a glucocorticoid-induced increase in spontaneous calcium activity on GR. Finally, we present a proof of concept for application in vivo. KH-103 opens opportunities for a more lucid interpretation of GR functions with translational potential.


  • Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs)

    by Ahmed Besheer, Hanns-Christian Mahler, Anja Matter-Schwald, Sergio Mompart Barrenechea, Martin Vogt, Pascal Chalus, Pauline Heymes, Timothy Pillow, Andrea Kirste, Patrick Favrod, et al.

    Purpose Health care professionals can be exposed to hazardous drugs such as cytostatics during preparation of drugs for administration. Closed sytem transfer devices (CSTDs) were introduced to provide protection for healthcare professional against unintended exposure to hazardous drugs. The interest in CSTDs has significantly increased after USP monograph was issued. The majority of the studies published so far on CSTDs have focused on their “containment” function. However, other important attributes for CSTDs with potential importance for product quality impact are not yet fully evaluated. Methods In the current study, we evaluated four sytems from different suppliers, in combination with different container closure systems (CCS), using solutions of different viscosity and surface tension. The different CSTD / CCS combinations were tested for (a) containment (integrity) using a highly sensitive helium leak test, (b) the force required for mounting the vial adaptor, (c) contribution to visible and subvisible particles as well as (d) the hold-up volume. Results Results show that the majority of CSTDs may have leaks varying in size, and that some of them generated visible particles due to stopper coring and subvisible particles, both due to silicon oil and particulate contaminations of the Devices. Finally, the holdup volume was up to 1 mL depending on the CSTD type, vial size and solution viscosity. Conclusion These results show that there is a need to evaluate the compatibility of CSTD systems to select the best system for the intended use and that CSTDs may adversely impact product quality and delivered dose.